RD Fund investments are focused on therapeutic companies with clinical stage, or near to clinical stage programs focused on inherited retinal disease (IRD) conditions. The Fund is geographically agnostic, and has an allocation range from $250k seed investments to $8M with a typical investment size between $2M and $5M. The RD Fund is unique in that it leverages the full weight of the Foundation Fighting Blindness’s knowledge and resources including: natural history studies, My Retinal Tracker, world class scientific advisory board and clinical consortium. As a result, the RD Fund leverages both internal resources, and investment capital to attract additional investors and is open to using financial instruments including convertible notes, equity, fixed multiple return on investments, and royalties, with a preference for ground floor equity investments. The RD Fund currently has ongoing investments in SparingVision, Nacuity, and ProQR.